Sterling Investment Advisors Ltd. Sells 13,000 Shares of Globus Medical, Inc. $GMED

Sterling Investment Advisors Ltd. trimmed its position in Globus Medical, Inc. (NYSE:GMED) by 8.3% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 144,023 shares of the medical device company’s stock after selling 13,000 shares during the quarter. Globus Medical accounts for approximately 2.2% of Sterling Investment Advisors Ltd.’s portfolio, making the stock its 9th largest holding. Sterling Investment Advisors Ltd. owned about 0.11% of Globus Medical worth $12,575,000 at the end of the most recent quarter.

Other large investors also recently modified their holdings of the company. Advisory Services Network LLC purchased a new position in shares of Globus Medical in the 3rd quarter worth about $26,000. EverSource Wealth Advisors LLC raised its holdings in shares of Globus Medical by 74.3% in the 2nd quarter. EverSource Wealth Advisors LLC now owns 462 shares of the medical device company’s stock worth $27,000 after purchasing an additional 197 shares during the period. SBI Securities Co. Ltd. raised its holdings in shares of Globus Medical by 98.2% in the 4th quarter. SBI Securities Co. Ltd. now owns 337 shares of the medical device company’s stock worth $29,000 after purchasing an additional 167 shares during the period. Parallel Advisors LLC raised its holdings in shares of Globus Medical by 45.1% in the 3rd quarter. Parallel Advisors LLC now owns 557 shares of the medical device company’s stock worth $32,000 after purchasing an additional 173 shares during the period. Finally, Mirae Asset Global Investments Co. Ltd. purchased a new position in shares of Globus Medical in the 3rd quarter worth about $36,000. 95.16% of the stock is currently owned by hedge funds and other institutional investors.

Globus Medical Stock Performance

Shares of NYSE:GMED opened at $84.84 on Tuesday. The company has a market cap of $11.52 billion, a P/E ratio of 19.73, a PEG ratio of 1.75 and a beta of 1.00. Globus Medical, Inc. has a one year low of $51.79 and a one year high of $101.40. The business’s 50-day simple moving average is $87.27 and its 200 day simple moving average is $88.15.

Globus Medical (NYSE:GMED) last announced its earnings results on Thursday, May 7th. The medical device company reported $1.12 EPS for the quarter, beating the consensus estimate of $0.92 by $0.20. The business had revenue of $759.85 million for the quarter, compared to the consensus estimate of $740.35 million. Globus Medical had a return on equity of 13.46% and a net margin of 18.92%.The company’s revenue was up 27.0% on a year-over-year basis. During the same period last year, the business posted $0.68 EPS. Globus Medical has set its FY 2026 guidance at 4.700-4.800 EPS. Analysts predict that Globus Medical, Inc. will post 4.74 earnings per share for the current year.

Insider Activity at Globus Medical

In related news, EVP Kelly Huller sold 20,000 shares of the firm’s stock in a transaction dated Wednesday, February 25th. The stock was sold at an average price of $94.50, for a total transaction of $1,890,000.00. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Insiders own 18.38% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities analysts have recently commented on GMED shares. Wall Street Zen downgraded Globus Medical from a “strong-buy” rating to a “buy” rating in a report on Saturday, May 9th. Truist Financial set a $115.00 price objective on Globus Medical in a report on Wednesday, February 25th. Barclays raised their price objective on Globus Medical from $118.00 to $123.00 and gave the stock an “overweight” rating in a report on Wednesday, February 25th. Zacks Research upgraded Globus Medical from a “hold” rating to a “strong-buy” rating in a report on Tuesday, March 3rd. Finally, Weiss Ratings restated a “hold (c+)” rating on shares of Globus Medical in a report on Wednesday, April 15th. Two research analysts have rated the stock with a Strong Buy rating, nine have issued a Buy rating and five have assigned a Hold rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $106.36.

Globus Medical Company Profile

Globus Medical, Inc (NYSE:GMED) is a leading medical device company specializing in musculoskeletal solutions for spine and orthopaedic applications. Founded in 2003 by David C. Paul and headquartered in Audubon, Pennsylvania, the company develops, manufactures and markets implantable devices and surgical instruments designed to treat spinal disorders and promote bone healing. Its product portfolio encompasses solutions for minimally invasive and open surgical procedures, including interbody fusion devices, pedicle screw systems, and biologics used to enhance fusion outcomes.

In addition to its core spine business, Globus Medical has expanded into robotics and navigation systems to support precision and efficiency in the operating room.